Positionspapier zum Post-COVID-Syndrom
Deleted Journal,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 3, 2025
COVID-19 Infection and Coronary Plaque Progression: An Early Warning of a Potential Public Health Crisis
Radiology,
Год журнала:
2025,
Номер
314(2)
Опубликована: Фев. 1, 2025
HomeRadiologyVol.
314,
No.
2
Previous
Reviews
and
CommentaryFree
AccessEditorialCOVID-19
Infection
Coronary
Plaque
Progression:
An
Early
Warning
of
a
Potential
Public
Health
CrisisJonathan
R.
Weir-McCall
,
Jack
S.
BellJonathan
BellAuthor
AffiliationsFrom
the
Department
Cardiovascular
Imaging,
Biomedical
Engineering
Imaging
Sciences,
King's
College
London,
England
(J.R.W.M.);
Radiology,
Royal
Brompton
Hospital,
Guys
St.
Thomas'
NHS
Trust,
Westminster
Bridge
Rd,
4th
Fl,
Lambeth
Wing,
Office
Suite
2,
London
SE1
7EH,
Liverpool
Center
for
Science
at
University
Liverpool,
John
Moores
Heart
Chest
(J.S.B.).Address
correspondence
to
J.R.W.M.
(email:
[email
protected]).Jonathan
BellPublished
Online:Feb
4
2025https://doi.org/10.1148/radiol.243767See
also
article
by
Dai
et
al
in
this
issue.MoreSectionsPDF
ToolsAdd
favoritesCiteTrack
CitationsPermissionsReprints
ShareShare
onFacebookXLinked
In
See
issue.Jonathan
is
senior
lecturer
cardiothoracic
radiologist
Hospital.
His
research
interests
lie
use
cardiovascular
CT
better
understanding
how
these
can
be
used
improve
patient
treatment
outcomes
structural
coronary
artery
disease.
He
sits
on
guideline
committee
SCCT,
Certification
Accreditation
Committee
EACVI
Diagnostics
Advisory
NICE.Download
as
PowerPointJack
Bell
cardiology
registrar
National
Institute
Research
academic
clinical
fellow
Centre
Science.
center
around
integrating
multimodal
data,
including
imaging,
risk
prediction
diseases.Download
PowerPoint
5
years
since
outbreak
COVID-19
pandemic,
there
have
been
over
750
million
documented
cases,
with
100
United
States
alone
(1).
With
advent
mass
vaccinations
growing
population
immunity,
morbidity
mortality
associated
acute
infection
has
improved
substantially.
Resolution
does
not
result
cessation
consequences
COVID-19,
however.
Long-term
sequelae
observed
across
multiple
organ
systems
include
1.6-fold
higher
events
1
year
after
(2).
The
precise
mechanisms
which
influences
remain
uncertain,
although
one
most
compelling
hypotheses
an
interaction
between
atherosclerosis.
Atherosclerosis
chronic
inflammatory
disease,
endothelial
dysfunction
accumulation
low-density
lipoprotein
cholesterol
vessel
intima
leading
complex
cascade
involving
both
innate
adaptive
immune
system.
Both
autoimmune
conditions
(eg,
rheumatoid
arthritis,
bowel
psoriasis)
viral
infections
HIV)
potentiate
relevant
pathways,
accelerated
plaque
formation,
progression,
instability
(3,4).
evidence
less
clear
infections,
studies
calcium
progression
following
pneumonia
reduced
influenza
vaccine
recipients
(5,6).
Preclinical
shown
plausible
could
influence
atherosclerosis,
direct
effects
vascular
endothelium
platelets
via
angiotensin-converting
enzyme
receptor
indirect
through
induction
systemic
inflammation
(7).
However,
atherosclerosis
lacking.
angiography
(CCTA)
ideal
tool
addressing
question.
It
enables
noninvasive
quantitative
assessment
burden
atherosclerotic
within
entire
tree.
This
agree
well
invasive
detect
response,
predict
events.
information
further
complemented
pericoronary
adipose
tissue
(PCAT)
attenuation,
measured
same
time.
elevated
PCAT
attenuation
suggestive
inflammation.
A
recent
study
158
patients
demonstrated
increased
prior
(8).
While
useful
first
glimpse
into
inflammation,
analysis
did
examine
volume,
nor
it
consider
consequence
elevation
attenuation.
issue
(9)
harness
serial
CCTA
scans
alongside
state-of-the-art
image
investigate
associates
outcomes.
retrospective
single-center
analyzed
803
least
two
examinations
performed
median
interval
3
apart.
cohort
was
stratified
according
whether
confirmed
occurred
final
examination.
total
690
2108
plaques
had
113
480
not.
groups
were
matched
baseline
terms
traditional
factors;
medications;
C-reactive
protein
levels;
infection;
vaccination
status;
features,
volumes,
high-risk
key
finding
that
exhibited
greater
annualized
percent
atheroma
volume
(mean,
0.90%
per
±
0.91
[SD]
vs
0.62%
0.68;
P
<
.001)
noncalcified
0.78%
0.79
0.42%
0.45;
compared
without
infection.
Plaques
more
likely
progress
(incidence,
21.0%
15.8%;
=
.03)
exhibit
27.1%
19.8%;
At
causal
mediation
analysis—which
assumes
no
unmeasured
confounders
association
exposure,
mediators,
outcomes—PCAT
accounted
10.3%
between-group
difference
progression.
Clinical
recorded
9
months
examination
defined
lesion
level,
target
failure
end
point
encompassing
cardiac
death,
myocardial
infarction,
revascularization;
major
adverse
all-cause
hospitalization
unstable
angina.
Patients
(10.4%
3.1%;
adjusted
hazard
ratio,
2.90;
(20.1%
3.8%;
4.8;
.002)
those
should
commended
their
comprehensive
large
cohort,
providing
insights
potential
longer-term
COVID-19.
Whereas
findings
certainly
suggest
strong
link
infection,
always
confounding,
inherent
observational
studies.
particular,
behavior
acquiring
such
mask
wearing,
status,
adherence
public
health
regulations,
related
reduction
behaviors,
preventative
lifestyle
measures
medication.
similar
levels
vaccination,
before
period,
medication
use,
provides
some
reassurance
regard,
course
guarantee
adherence.
excluded
who
required
interscan
interval,
thereby
excluding
highest
risk.
Therefore,
possible
severity
consequent
Replication
multicenter
setting,
ideally
range
ethnic
backgrounds,
validate
Asian
rates
are
high.
Overall,
important
hypothesis-generating
clinically
understudied
area.
mild
raises
interesting
questions
about
mechanism.
Although
shared
biologic
pathways
linking
so-called
cytokine
storm
severe
COVID-19—namely
inflammasome
activation
downstream
interleukin
1β,
6,
release—this
Indeed,
high-sensitivity
follow-up
normal
study.
Instead,
incidence
persistent
but
localized
Mechanisms
here
antigen
persistence,
dysregulation,
dysfunction,
oxidative
stress
extending
postacute
phase
Causal
suggested
only
responsible
overall
contribution
underestimated
because
7
months.
If
driving
force
would
expect
maximal
peri-infection
period
then
quiescing.
Consistent
this,
imaged
than
Further
work
aid
temporal
relationship
underlying
association,
determine
specific
question
mechanism
essential
establishing
mitigate
guiding
we
targeting
earliest
during
or
long
term.
From
perspective,
concerning
approach
800
cases
worldwide
replicated
other
populations,
spectrum
severity,
becomes
best
integrate
care
pathway.
Some
calculators,
QRISK3,
already
incorporate
arthritis
lupus
erythematosus
calculations,
reported
ratios
(10).
quantification
may
help
refine
risk,
given
scale
numbers
infected,
integration
cost-effective
manner
challenging.
Given
magnitude
hand,
action
bring
together
trials
necessary
assess
strategies,
anti-inflammatory
medications
statins,
reduce
prevent
future
events.Disclosures
conflicts
interest:
No
relationships.
J.S.B.
supported
fellowship
from
Hospital
Charity.References1.
WHO
dashboard:
cases.
World
Organization.
https://data.who.int/dashboards/covid19/cases.
Accessed
December
3,
2024.
Google
Scholar2.
Xie
Y,
Xu
E,
Bowe
B,
Al-Aly
Z.
Nat
Med
2022;28(3):583–590.
Medline
Scholar3.
Hemmat
N,
Ebadi
A,
Badalzadeh
R,
Memar
MY,
Baghi
HB.
Viral
Eur
J
Clin
Microbiol
Infect
Dis
2018;37(12):2225–2233.
Scholar4.
Porsch
F,
Binder
CJ.
Autoimmune
diseases
Rev
Cardiol
2024;21(11):780–807.
Scholar5.
Behrouzi
Bhatt
DL,
Cannon
CP,
al.
Association
Influenza
Vaccination
Risk:
Meta-analysis.
JAMA
Netw
Open
2022;5(4):e228873.
Scholar6.
Corrales-Medina
VF,
Dwivedi
G,
Taljaard
M,
pneumonia:
MESA
PLoS
One
2018;13(2):e0191750.
Scholar7.
Chidambaram
V,
Kumar
Sadaf
MI,
Initiation
Progression
Atherosclerosis:
Pathophysiology
During
Beyond
Acute
Phase.
JACC
Adv
2024;3(8):101107.
Scholar8.
Mátyás
BB,
Benedek
I,
Blîndu
Elevated
FAI
Index
Pericoronary
Inflammation
Identifies
Increased
Risk
Vulnerability
Infection.
Int
Mol
Sci
2023;24(8):7398.
Scholar9.
Tang
X,
Hu
SARS-CoV-2
Radiology
2025;314(2):e240876.
Scholar10.
Hippisley-Cox
J,
Coupland
C,
Brindle
P.
Development
validation
QRISK3
algorithms
estimate
disease:
prospective
BMJ
2017;357:j2099.
ScholarArticle
HistoryReceived:
Dec
10
2024Revision
requested:
19
received:
2024Accepted:
20
2024Published
online:
Feb
04
2025
FiguresReferencesRelatedDetailsAccompanying
ArticleSARS-CoV-2
Atherosclerotic
Angiography
Adverse
EventsFeb
2025Radiology
Vol.
Metrics
Altmetric
Score
PDF
download
Язык: Английский
Variability in Arterial Stiffness and Vascular Endothelial Function After COVID-19 During 1.5 Years of Follow-Up—Systematic Review and Meta-Analysis
Life,
Год журнала:
2025,
Номер
15(4), С. 520 - 520
Опубликована: Март 21, 2025
Increasing
long-term
observations
suggest
that
coronavirus
disease
2019
(COVID-19)
vasculopathy
may
persist
even
1.5
years
after
the
acute
phase,
potentially
accelerating
development
of
atherosclerotic
cardiovascular
diseases.
This
study
systematically
reviewed
variability
brachial
flow-mediated
dilation
(FMD)
and
carotid-femoral
pulse
wave
velocity
(cfPWV)
from
phase
COVID-19
through
16
months
follow-up
(F/U).
Databases
including
PubMed,
Web
Science,
MEDLINE,
Embase
were
screened
for
a
meta-analysis
without
language
or
date
restrictions
(PROSPERO
reference
CRD42025642888,
last
search
conducted
on
1
February
2025).
The
quality
included
studies
was
assessed
using
Newcastle–Ottawa
Quality
Scale.
We
considered
all
(interventional
pre-post
studies,
prospective
observational
randomized,
non-randomized
trials)
FMD
cfPWV
in
adults
(aged
≥
18
years)
with
laboratory-confirmed
compared
non-COVID-19
controls
changes
these
parameters
during
F/U.
Twenty-one
reported
differences
FMD,
examined
between
patients
control
groups
various
stages:
acute/subacute
(≤30
days
onset),
early
(>30–90
days),
mid-term
(>90–180
late
(>180–270
very
(>270
days)
post-COVID-19
recovery.
Six
while
nine
did
so
Data
14
(627
cases
694
controls)
15
(578
703
our
meta-analysis.
showed
significant
decrease
to
(standardized
mean
difference
[SMD]=
−2.02,
p
<
0.001),
partial
improvements
noted
recovery
(SMD
=
0.95,
0.001)
0.92,
0.006).
Normalization
observed
0.12,
0.69).
In
contrast,
values,
which
higher
than
1.27,
remained
elevated
throughout
F/U,
no
except
(SMD=
−0.39,
0.001).
recovery,
values
those
0.45,
0.010).
manuscript,
we
discuss
how
factors,
severity
COVID-19,
persistence
syndrome,
patient’s
initial
vascular
age,
depending
metrics
age
risk
influenced
time
degree
improvement.
Язык: Английский
Revisiting the Role of Platelet-Activating Factor in COVID-19-Induced Cardiovascular Complications
Frontiers in Bioscience-Landmark,
Год журнала:
2025,
Номер
30(3)
Опубликована: Март 17, 2025
IMR
Press
is
a
leading
publisher
of
open
access
peer-reviewed
biomedical
and
life
sciences
journals.
We
aim
to
facilitate
the
dissemination
high-quality
research
in
area
science.
With
long
tradition
wide
readership,
dedicated
making
positive
contributions
academics,
corporate
libraries
as
well
readers
authors.
All
editors
will
provide
best
service
for
researchers,
allowing
them
have
easy
smooth
publication
experience
helping
maximize
impact
visibility
their
research.
Язык: Английский
The Involvement and Manifestations of SARS-CoV-2 Virus in Cardiovascular Pathology
Sofia Teodora Hărșan,
Anca Sin
Medicina,
Год журнала:
2025,
Номер
61(5), С. 773 - 773
Опубликована: Апрель 22, 2025
Although
the
acute
phase
of
COVID-19
pandemic
has
subsided,
emergence
post-COVID-19
condition
presents
a
new
and
complex
public
health
challenge,
characterized
by
persistent,
multisystem
symptoms
that
can
endure
for
weeks
or
months
after
initial
infection
with
SARS-CoV-2
virus,
significantly
affecting
survivors’
quality
life.
Among
most
concerning
sequelae
are
cardiovascular
complications,
which
encompass
broad
spectrum
conditions,
including
arrhythmias,
myocardial
damage,
postural
orthostatic
tachycardia
syndrome.
This
narrative
review
explores
burden
on
reviewing
latest
relevant
findings
in
literature
highlighting
different
aspects
COVID-19’s
involvement.
investigates
pathophysiological
mechanisms
underlying
involvement
condition,
focus
direct
viral
invasion
via
ACE2
receptors,
immune-mediated
injury,
cytokine
storm,
systemic
inflammation,
endothelial
dysfunction,
mitochondrial
injury.
The
interplay
between
pre-existing
diseases,
such
as
hypertension,
atherosclerosis,
diabetes,
atrial
fibrillation,
is
also
explored,
revealing
individuals
conditions
at
heightened
risk
both
severe
illness
long-term
complications.
Long-term
immune
activation
persistence
antigens
increasingly
recognized
contributors
to
ongoing
even
mild
asymptomatic
infections.
As
healthcare
system
continues
adapt
consequences
pandemic,
deeper
understanding
these
manifestations
essential.
knowledge
will
inform
development
targeted
strategies
prevention,
clinical
management,
rehabilitation
affected
patients.
Furthermore,
insights
gained
from
intersection
be
instrumental
shaping
responses
future
epidemics,
necessity
multidisciplinary
approaches
patient
care
preparedness.
Язык: Английский
Proteomic Profiling of Endothelial Cell Secretomes After Exposure to Calciprotein Particles Reveals Downregulation of Basement Membrane Assembly and Increased Release of Soluble CD59
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(21), С. 11382 - 11382
Опубликована: Окт. 23, 2024
Calciprotein
particles
(CPPs)
are
essential
circulating
scavengers
of
excessive
Ca
Язык: Английский
Is Platelet-Activating Factor the Missing Link Between COVID-19 and Atherosclerosis?
JACC Advances,
Год журнала:
2024,
Номер
3(12), С. 101397 - 101397
Опубликована: Ноя. 9, 2024
Язык: Английский
Reply
JACC Advances,
Год журнала:
2024,
Номер
3(12), С. 101396 - 101396
Опубликована: Ноя. 11, 2024
Colchicine: Repositioning an “ancient” medicine in the 21st century
Rheumatology Science and Practice,
Год журнала:
2024,
Номер
62(5), С. 445 - 464
Опубликована: Окт. 31, 2024
The
main
indications
for
colchicine
treatment
until
recently
were
gout,
pericarditis,
familial
Mediterranean
fever
and
some
other
auto-inflammatory
diseases.
expansion
of
(repositioning)
the
use
in
direction
prevention
cardiovascular
complications
should
be
considered
as
one
major
events
medicine
XXI
century.
Deciphering
role
inflammation
most
important
mechanism
development
atherosclerosis
has
created
prerequisites
concept
anti-inflammatory
therapy
atherosclerosis,
which
low-dose
can
take
an
place,
complementing
effects
aspirin,
statins
antihypertensive
therapy.
analysis
materials
from
randomized
placebo-controlled
studies
indicates
a
decrease
frequency
patients
with
coronary
heart
disease
(by
31%)
who
have
suffered
myocardial
infarction
23%),
well
33%),
stroke,
need
revascularization
mortality.
low
dose
(0.5
mg/day)
is
approved
by
U.S.
Food
Drug
Administration
disease.
It
assumed
that
future
will
place
pathology
associated
atherosclerotic
vascular
Язык: Английский